PL207522B1 - Zastosowanie acetylo-L-karnityny w połączeniu z biotyną - Google Patents

Zastosowanie acetylo-L-karnityny w połączeniu z biotyną

Info

Publication number
PL207522B1
PL207522B1 PL367630A PL36763002A PL207522B1 PL 207522 B1 PL207522 B1 PL 207522B1 PL 367630 A PL367630 A PL 367630A PL 36763002 A PL36763002 A PL 36763002A PL 207522 B1 PL207522 B1 PL 207522B1
Authority
PL
Poland
Prior art keywords
carnitine
acetyl
biotin
acid
day
Prior art date
Application number
PL367630A
Other languages
English (en)
Polish (pl)
Other versions
PL367630A1 (en
Inventor
Menotti Calvani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of PL367630A1 publication Critical patent/PL367630A1/xx
Publication of PL207522B1 publication Critical patent/PL207522B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL367630A 2001-05-29 2002-05-24 Zastosowanie acetylo-L-karnityny w połączeniu z biotyną PL207522B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
PCT/IT2002/000338 WO2002096410A1 (en) 2001-05-29 2002-05-24 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus

Publications (2)

Publication Number Publication Date
PL367630A1 PL367630A1 (en) 2005-03-07
PL207522B1 true PL207522B1 (pl) 2010-12-31

Family

ID=11455558

Family Applications (1)

Application Number Title Priority Date Filing Date
PL367630A PL207522B1 (pl) 2001-05-29 2002-05-24 Zastosowanie acetylo-L-karnityny w połączeniu z biotyną

Country Status (18)

Country Link
US (2) US20040142879A1 (enExample)
EP (1) EP1399142B1 (enExample)
JP (1) JP4381685B2 (enExample)
KR (1) KR20040010666A (enExample)
AT (1) ATE333274T1 (enExample)
CA (1) CA2448244C (enExample)
CY (1) CY1105403T1 (enExample)
CZ (1) CZ297743B6 (enExample)
DE (1) DE60213237T2 (enExample)
DK (1) DK1399142T3 (enExample)
ES (1) ES2268053T3 (enExample)
HU (1) HUP0400060A2 (enExample)
IT (1) ITRM20010294A1 (enExample)
MX (1) MXPA03010921A (enExample)
PL (1) PL207522B1 (enExample)
PT (1) PT1399142E (enExample)
SK (1) SK287832B6 (enExample)
WO (1) WO2002096410A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230002B1 (en) * 2000-12-15 2015-04-28 Sigma Tau Ind Farmaceuti Use of l-carnitine for preparation of compositions for stabilizing the proteins
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
ES2546619T3 (es) * 2007-03-21 2015-09-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composición útil para la prevención de la diabetes tipo 2 y sus complicaciones en pacientes pre-diabéticos con resistencia a la insulina
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes

Also Published As

Publication number Publication date
DK1399142T3 (da) 2006-10-30
WO2002096410A1 (en) 2002-12-05
CZ20033221A3 (cs) 2004-06-16
KR20040010666A (ko) 2004-01-31
US20080269307A1 (en) 2008-10-30
ITRM20010294A0 (it) 2001-05-29
ITRM20010294A1 (it) 2002-11-29
MXPA03010921A (es) 2004-02-27
SK15852003A3 (sk) 2004-04-06
ES2268053T3 (es) 2007-03-16
CA2448244A1 (en) 2002-12-05
US20040142879A1 (en) 2004-07-22
PT1399142E (pt) 2006-10-31
EP1399142B1 (en) 2006-07-19
CY1105403T1 (el) 2010-04-28
HUP0400060A2 (hu) 2004-04-28
JP4381685B2 (ja) 2009-12-09
EP1399142A1 (en) 2004-03-24
CZ297743B6 (cs) 2007-03-21
JP2004532866A (ja) 2004-10-28
DE60213237T2 (de) 2007-08-02
DE60213237D1 (de) 2006-08-31
CA2448244C (en) 2010-11-02
ATE333274T1 (de) 2006-08-15
SK287832B6 (sk) 2011-11-04
US8053472B2 (en) 2011-11-08
PL367630A1 (en) 2005-03-07

Similar Documents

Publication Publication Date Title
SK283853B6 (sk) Terapeutická/výživová kompozícia pre diabetikov
RU2223771C2 (ru) Лечение диабета ii типа с использованием хрома/биотина
JP3699124B2 (ja) タイプｉｉ糖尿病のピコリン酸クロム高用量治療
WO2011075741A1 (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
US20050013887A1 (en) Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
DE19818563A1 (de) Verwendung von alpha-Liponsäure zur Verringerung des Appetits und/oder zur Körpergewichtsreduzierung
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
WO2007033082A2 (en) Compositions comprising dimethyl sulfoxide (dmso)
KR100530878B1 (ko) Ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 및 긴 사슬의알카놀을 함유하는 조성물
EP4331583A1 (en) Blood carnitine-increasing agent
JPH11246410A (ja) インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
JP5697337B2 (ja) ２型糖尿病の処置に有用な組成物
JP2021520403A (ja) 糖尿病予防・治療用の医薬品組成物及びその用途
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
CN118871096A (zh) 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物
DE10113974A1 (de) Verwendung von racemischer und enantiomerenreiner Dihydroliponsäure oder deren Derivate zur Körpergewichtsreduzierung und/oder zur Verringerung des Appetits
WO2002072078A9 (de) Verwendung von zuckerphosphaten, aminosäure und deren analogen we z. b. carbomethoxypropionylcyanid zur gewichtsreduzierung oder diabeteskomplikationen
HK1135030B (en) Composition useful for the treatment of type 2 diabetes

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20130524